Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Michel Moutschen"'
Autor:
Frédéric Frippiat, Keith Durkin, Cécile Kremer, Vincent Bours, Maria Artesi, Christel Faes, Niel Hens, Médéa Locquet, Loic Duchene, Anne-Sophie Sauvage, Gilles Darcis, Christelle Meuris, Samira Azarzar, Marie-Pierre Hayette, Patricia Dellot, Philippe Leonard, Cécile Meex, Nicole Maréchal, Karine Fombellida, Jean-Baptiste Giot, Olivier Bruyère, Justine Defêche, Michel Moutschen, Anton Geerinck
Publikováno v:
JAMA Network Open
Key Points Question What is the possible role of children in SARS-CoV-2 transmission? Findings This cohort study including 63 children and 118 adults found no significant difference between the number of children and the number of adults testing posi
Autor:
Faustin Kitetele Ndolumingu, Marcel Mbula Mambimbi, Nadine Mayasi Ngongo, Murielle Longokolo Mashi, Gilles Darcis, Hippolyte Situakibanza Nani-Tuma, Ben Bepouka Izizag, Michel Moutschen, Nathalie Maes
Publikováno v:
AIDS Research and Therapy
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-7 (2021)
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-7 (2021)
Introduction Late presentation for HIV care is a well-described issue for the success of ART outcomes and the cause of higher morbidity, mortality and further transmission. Monitoring the level of late presentation and understanding the factors assoc
Autor:
Benoît Misset, Eric Hoste, Anne Françoise Donneau, David Grimaldi, Geert Meyfroidt, Michel Moutschen, Veerle Compernolle, André Gothot, Daniel Desmecht, Mutien Garigliany, Tome Najdovski, Pierre François Laterre
Publikováno v:
BMC pulmonary medicine, Vol. 21, no.1, p. 248 [1-2] (2021)
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-2 (2021)
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-2 (2021)
BMC Pulmonary Medicine
The COVID-19 pandemic reached Europe in early 2020. Convalescent plasma is used without a consistent evidence of efficacy. Our hypothesis is that passive immunization with plasma collected from patients having contracted COVID-19 and developed specif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e28ab42c054459d4ca3c41507328da
https://hdl.handle.net/2078.1/259133
https://hdl.handle.net/2078.1/259133
Autor:
Anne Luyten, Geert Verbeke, David Grimaldi, Michel Moutschen, Marta Romano, Cyril Barbezange, Michel Toungouz Nevessignsky, Veerle Compernolle, Daniel Desmecht, Geert Meyfroidt, Jean-Cyr Yombi, Peter Verhamme, Johan van Griensven, Lucie Seyler, Bart N. Lambrecht, Alexander Schauwvlieghe, Tatjana Geukens, Kevin K. Ariën, Katleen Vandenberghe, Myriam Cleeren, Timothy Devos, Erika Vlieghe, Nicolas Dauby, Laurens Liesenborghs, Piet Maes
Publikováno v:
TRIALS
Trials, Vol. 21, no.1, p. 981 [1-15] (2020)
Trials
Trials, 21 (1
Trials, Vol 21, Iss 1, Pp 1-15 (2020)
Trials, Vol. 21, no.1, p. 981 [1-15] (2020)
Trials
Trials, 21 (1
Trials, Vol 21, Iss 1, Pp 1-15 (2020)
Background The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb1f49de495d999ebc8d52579103a94
https://biblio.vub.ac.be/vubir/(904d7a29-317f-4fe8-8952-19fbee924d52).html
https://biblio.vub.ac.be/vubir/(904d7a29-317f-4fe8-8952-19fbee924d52).html
Autor:
Michel Moutschen, Veerle Compernolle, Daniel Desmecht, David Grimaldi, Mutien-Marie Garigliany, Geert Meyfroidt, Tome Najdovski, Pierre-François Laterre, André Gothot, Anne-Françoise Donneau, Benoit Misset, Eric Hoste
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-9 (2020)
BMC pulmonary medicine, Vol. 20, no.1, p. 317 [1-9] (2020)
BMC pulmonary medicine, 20 (1
BMC PULMONARY MEDICINE
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-9 (2020)
BMC pulmonary medicine, Vol. 20, no.1, p. 317 [1-9] (2020)
BMC pulmonary medicine, 20 (1
BMC PULMONARY MEDICINE
Background: The COVID-19 pandemic reached Europe in early 2020. Convalescent plasma is used without a consistent evidence of efficacy. Our hypothesis is that passive immunization with plasma collected from patients having contracted COVID-19 and deve
Autor:
Douglas Cunningham, D. Ward, Mamta K. Jain, Faiza Ajana, Magda Opsomer, Anita Rachlis, Sharon Walmsley, Frank A. Post, Anders Blaxhult, Amanda Clarke, M. J. Galindo, Marcel Stoeckle, P.-M. Girardy, Karam Mounzer, David Shamblaw, U. F. Bredeek, L. Bhatti, J. J. Eron, Andrew Ustianowski, Mar Gutierrez, John Jezorwski, Javier O Morales-Ramirez, Antonio Rivero, M.A. Johnson, Gatell Jm, Erika Van Landuyt, Stéphane De Wit, A. Wilkin, Laurent Cotte, Cheryl McDonald, D. Murphy, Cynthia Brinson, Romana Petrovic, Olayemi Osiyemi, J. de Vente, I. Poizot-Martin, Juan Berenguer, Robin Dretler, J. Bailey, B. Rashbaum, Moti Ramgopal, A. Scribner, Yazdan Yazdanpanah, Eric Florence, A. Piekarska, Brian Gazzard, Chloe Orkin, W. Halota, Gary Richmond, Jacques Reynes, C. Ricart, C. Lucasti, Ignacio Pérez-Valero, Jason Brunetta, S. Shafran, Daniel Podzamczer, Franco Antonio Felizarta, Claudia Martorell, F. Post, Peter Ruane, Edwin DeJesus, J. Portilla Sogorb, C. Orkin, K. Tashima, Federico Pulido, Bernard Vandercam, F. Pulido, José L. Casado, Christine Katlama, Kimberley Brown, J Gasiorowski, A. Witor, Joseph J. Eron, Brian Conway, Andri Rauch, Jose R. Arribas, Michel Moutschen, H. Olivet, A. Scarsella, Leo Flamholc, A. Horban, D. Cunningham, Ronald Nahass, Félix Gutiérrez, G. Huhn, W.K. Henry, A. Thalme, S De Wit, Jan Fehr, Debbie Hagins, José Antonio Iribarren, J.-M. Molina, S. Henn, F Raffi, Juan A. Pineda, Marina B. Klein, Eugenia Negredo, Hernando Knobel, J. Slim, P. Benson, L. Waters, E. Teicher, Linos Vandekerckhove, Craig A. Dietz, Magnus Gisslén, Joel E. Gallant, J. Gathe, P. Shalit, D. Prelutsky, G. Voskuhl, D. Rey, E. Van Wijngaerden, Anthony Mills, Erkki Lathouwers, Carl J. Fichtenbaum, I. Brar, Gordon Crofoot, Veerle Hufkens, I. Santos Gil
Publikováno v:
Antiviral Research
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017eb51bc97390ae19e12fb2aea5fdc8
http://hdl.handle.net/2445/171213
http://hdl.handle.net/2445/171213
Autor:
Marianne Lecomte, Philippe Leonard, Anne-Sophie Sauvage, Alexander O. Pasternak, Gilles Darcis, Dolores Vaira, Majdouline Elmoussaoui, Karine Fombellida, Frédéric Frippiat, Michel Moutschen, Christelle Meuris, Françoise Uurlings, Nathalie Maes
Publikováno v:
Antimicrob Agents Chemother
Antimicrobial agents and chemotherapy, 64(3):e01902. American Society for Microbiology
Antimicrobial agents and chemotherapy, 64(3):e01902. American Society for Microbiology
HIV persistence despite therapy contributes to chronic immune activation and inflammation, increasing the risk of aging-associated events in HIV-infected individuals. We sought here to better understand the complex link between clinical and treatment
Autor:
Bernard Vandercam, Marc Delforge, Jean-Christophe Goffard, Stéphane De Wit, Paul Lacante, Patrick Lacor, Eric Van Wijngaerden, Eric Florence, Linos Vandekerkhove, Michel Moutschen, Maartje van Frankenhuijsen, Rémy Demeester
Publikováno v:
Acta clinica Belgica, Vol. 74, no.3, p. 143-150 (2019)
Objectives: This 5-year follow-up study aimed to assess clinical outcomes of HIV-1 infected adults treated with atazanavir (ATV) in clinical practice in Belgium, to describe patient profiles and characteristics, as well as treatment safety. Methods:
Autor:
Michel Moutschen, Linos Vandekerckhove, Rémy Demeester, Eric Van Wijngaerden, Eric Florence, Jean-Christophe Goffard, Hilde Piryns, Pushpike Thilakarathne, Bernard Vandercam, Stéphane De Wit
Publikováno v:
Acta Clinica Belgica. :1-7
Background Once daily (QD) ritonavir or cobicistat-boosted darunavir (DRV/b), in combination with other antiretrovirals (ARVs), is recommended as a first-line option for human immunodeficiency virus-infected patients in European and USA guidelines. T
Autor:
Murielle Longokolo Mashi, Ben Bepouka Izizag, Hippolyte Situakibanza Nanituna, Marcel Mbula Mambimbi, Gilles Darcis, Nadine Mayasi Ngongo, Nathalie Maes, François Lepira Bompeka, Michel Moutschen
Publikováno v:
PLoS ONE, Vol 16, Iss 11, p e0259073 (2021)
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE
Background The benefits of antiretroviral therapy (ART) underpin the recommendations for the early detection of HIV infection and ART initiation. Late initiation (LI) of antiretroviral therapy compromises the benefits of ART both individually and in